Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso—Implications for introduction of PsA-TT into the Expanded Programme on Immunization. Issue 12 (17th March 2015)

• Record Type: Journal Article
• Authors: Meyer, Sarah A.; Kambou, Jean Ludovic; Cohn, Amanda; Goodson, James L.; Flannery, Brendan; Medah, Isaïe; Messonnier, Nancy; Novak, Ryan; Diomande, Fabien; Djingarey, Mamoudou H.; Clark, Thomas A.; Yameogo, Issaka; Fall, Amadou; Wannemuehler, Kathleen
• Is Part Of: Vaccine. Volume 33:Issue 12(2015)
• Page Start: 1492
• Page End: 1498
• Publication Date: 2015-03-17
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.01.043
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Evaluation of MCV coverage will help guide successful PsA-TT introduction into EPI.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">A national survey was conducted in Burkina Faso to assess PsA-TT and MCV coverage.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">PsA-TT campaign coverage was 95.9% with coverage greater than 90% in all regions.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Routine MCV coverage was 92.5%, but varied from 75.3% to 95.3% by region.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">Results identify regions at-risk for future suboptimal PsA-TT EPI coverage.</p> </list-item> </list> </p> </sec> </abstract>